Abstract Search

ba0005oc3.1 | Clinical trials, FGF-23 and focal osteoporosis | ECTS2016

Effect of odanacatib on bone density and estimated bone strength in postmenopausal women: a CT-based sub-study of the phase 3 long-term odanacatib fracture trial (LOFT)

Langdahl Bente , De Villiers Tobias , Keaveny Tony M , Engelke Klaus , Genant Harry , Ather Shabana , Giezek Hilde , Lombardi Antonio , Leung Albert , de Papp Anne

Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. In the Phase 3, Long-Term ODN Fracture Trial (LOFT; NCT00529373), ODN significantly reduced fracture risk. This imaging sub-study primarily investigated the effect of ODN on volumetric BMD (vBMD) of the lumbar spine (LS) and total hip (TH) using quantitative computed tomography (QCT).Women aged ≥65 without baseline radiographic vertebra...

0 shares

ba0005oc1.1 | Clinical trials and osteoporosis treatment | ECTS2016

Efficacy of odanacatib in postmenopausal women with osteoporosis: subgroup analyses of data from the phase 3 long-term odanacatib fracture trial (LOFT)

Saag Kenneth G , Alexandersen Peter , Benhamou Claude-Laurent , Gilchrist Nigel , Halse Johan , Michael Lewiecki E. , Lippuner Kurt , McClung Michael , Shiraki Masataka , DaSilva Carolyn A , Verbruggen Nadia , Scott Boyd B , Lombardi Antonio

Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. In the primary efficacy analysis of the Phase 3, Long-Term ODN Fracture Trial (LOFT; NCT00529373), ODN significantly reduced fracture risk compared with placebo in postmenopausal women with osteoporosis. Pre-specified subgroup analyses evaluated the efficacy of ODN in patient subgroups.Women aged ≥65 years, without baseline radiographic...

0 shares

Bone Abstracts

Effect of odanacatib on bone density and estimated bone strength in postmenopausal women: a CT-based sub-study of the phase 3 long-term odanacatib fracture trial (LOFT)

Efficacy of odanacatib in postmenopausal women with osteoporosis: subgroup analyses of data from the phase 3 long-term odanacatib fracture trial (LOFT)

BiosciAbstracts